Glofitamab Shows 75% Response Rate in Refractory CNS Lymphoma

Primary central nervous system lymphoma remains a therapeutic challenge for clinicians, particularly when the disease recurs after initial methotrexate-based regimens. While chimeric antigen receptor T-cell therapy and bispecific antibodies have transformed the management of systemic large B-cell lymphomas, their utility in primary brain malignancies is often limited by the blood-brain barrier (the physiological boundary that prevents many systemic drugs from entering the brain parenchyma) [1, 2]. Approximately 30% to 40% of patients with aggressive B-cell malignancies experience relapsed or refractory disease, and those with central nervous system involvement face a particularly difficult prognosis due to restricted drug delivery [3, 4]. Current guidelines emphasize the need for agents that can achieve therapeutic concentrations within the central nervous system while maintaining a manageable safety profile [1, 2]. A multicenter real-world analysis now provides data on the clinical activity and pharmacology of glofitamab, a CD20xCD3 bispecific antibody, in this difficult-to-treat population.